Trefoil is a biotechnology company that brings forward novel engineered FGF-1 compounds to treat endothelial cell mediated diseases.
Trefoil Therapeutics has raised $4.6M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in May 2025.
Trefoil Therapeutics's investors include Correlation Ventures, National Institutes of Health, Hatteras Venture Partners, FemHealth Ventures, Bios Partners.
Trefoil Therapeutics is headquartered in San Diego, United States.
Trefoil is a biotechnology company that brings forward novel engineered FGF-1 compounds to treat endothelial cell mediated diseases.
Trefoil Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Trefoil Therapeutics — Funding & Investors." VCBacked, May 6, 2025, https://www.vcbacked.co/company/trefoil-therapeutics. Accessed July 19, 2026.
VCBacked. (2025). Trefoil Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/trefoil-therapeutics
{{cite web |title=Trefoil Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/trefoil-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated